Smith Group Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Smith Group Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,190	Closed	-$20K	–	278
2021 Q4	$20K	Hold	4,190	–	–	﹤0.01%	253
2021 Q3	$22K	Hold	4,190	–	–	﹤0.01%	229
2021 Q2	$21K	Buy	4,190 +1,200	+40%	+$6.82K	﹤0.01%	230
2021 Q1	$20K	Sell	2,990 -69,640	-96%	-$386K	﹤0.01%	207
2020 Q4	$332K	Sell	72,630 -101,130	-58%	-$448K	0.02%	154
2020 Q3	$674K	Sell	173,760 -60	-0%	-$257	0.04%	116
2020 Q2	$827K	Buy	+173,820	New	+$716K	0.05%	108
2018 Q4	–	Sell	-110,980	Closed	-$2.46M	–	449
2018 Q3	$2.46M	Buy	+110,980	New	+$2.34M	0.07%	121

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smith Group Asset Management's AMRX Position: Q1 2022 in Review

Smith Group Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2022, closing a stake of 4,190 shares — an estimated $20K sold.

Smith Group Asset Management first reported a position in AMRX in Q3 2018 and held it in 8 quarters. The position peaked at $2.46M in Q3 2018. 168 funds tracked by Wall St. Rank hold AMRX as of Q1 2022.

Smith Group Asset Management reported no remaining Amneal Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 4,190 Amneal Pharmaceuticals shares in Q1 2022, an estimated $20K.
Smith Group Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Smith Group Asset Management's Amneal Pharmaceuticals position peaked at $2.46M in Q3 2018.
168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.